Last reviewed · How we verify
NCT04456426
Characteristics of Patients With COVID-19 in Meta State, Colombia
trial in COVID. Withdrawn.
31 December 2021
Quick facts
| Lead sponsor | Hospital Departamental de Villavicencio |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 September 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
Conditions studied
- COVID — all drugs for COVID →
- SARS-CoV 2 — all drugs for SARS-CoV 2 →
- SARS Pneumonia — all drugs for SARS Pneumonia →
- SARS (Disease) — all drugs for SARS (Disease) →
Sponsor
Hospital Departamental de Villavicencio
Who can join
Under 120, any sex, with COVID or SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study aims to collect detailed clinical information on confirmed or suspected patients of COVID-19 treated in hospitals from Meta State, Colombia. The objectives are: 1. To establish the characteristics of patients and healthcare workers treated with COVID-19. 2. To assess previous predisposing morbidity. 3. To detail clinical factors associated with complications. 4. To profile clinical indicators for severity and outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04456426
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID
Currently open trials in the same condition.
- NCT06744660 — Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test · NA · recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04447833 — Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome · Phase 1 · active not recruiting
- NCT04351347 — The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment · Phase 2, PHASE3 · recruiting
- NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
Other Hospital Departamental de Villavicencio trials
Trials by the same sponsor.
- NCT07530653 — Delayed Fluids in Hemorrhagic Shock Due to Severe Injuries. · not yet recruiting
- NCT07372092 — Complications of Surgical Geriatrics Hospitalized in the Orinoco Region · not yet recruiting
- NCT07249749 — Factor Associated With Mortality in the ICU · not yet recruiting
- NCT06048575 — Cholecystitis in Villavicencio Hospitals · completed
- NCT05938647 — Severe Dengue in Critical Care at Villavicencio, Colombia. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04456426 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Departamental de Villavicencio
- Last refreshed: 5 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04456426.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing